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Summary statement 
In high glucose conditions, nociceptive neurons are sensitised through the 
actions of HMGB1 acting though RAGE and PKC. This sensitisation is 
blocked by a vascular endothelial growth factor splice variant.  
 
Abstract  
Many potential causes for painful diabetic neuropathy have been proposed 
including actions of cytokines and growth factors. High mobility group protein 
B1 (HMGB1) is a RAGE agonist, increased in diabetes, that contributes to 
pain by modulating peripheral inflammatory responses. HMGB1 enhances 
nociceptive behaviour in naïve animals through an unknown mechanism. We 
tested the hypothesis that HMGB1 causes pain through direct neuronal 
activation of RAGE and alteration of nociceptive neuronal responsiveness.  
HMGB1 and RAGE expression were increased in skin and primary sensory 
(DRG) neurons of diabetic rats at times when pain behaviour was enhanced. 
Agonist-evoked TRPV1-mediated calcium responses increased in cultured 
DRG neurons from diabetic rats and in neurons from naïve rats exposed to 
high glucose concentrations. HMGB1-mediated increases in TRPV1-evoked 
calcium responses in DRG neurons were RAGE and PKC-dependent, and 
this was blocked by co-administration of the growth factor splice variant, 
VEGF-A165b. Pain behaviour and DRG RAGE expression increases were 
blocked by VEGF-A165b treatment of diabetic rats in vivo.  
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 HMGB-1-RAGE activation sensitizes DRG neurons in vitro. VEGF-A165b 
blocks HMGB-1/RAGE DRG activation, which may contribute to its analgesic 
properties in vivo. 
 
List of non-standard abbreviations 
AGE   advanced glycation end products 
AWERB Animal Welfare and Ethical Review Board 
DAPI  4',6-diamidino-2-phenylindole 
DRG  dorsal root ganglion/ganglia 
FPSZM1 N-benzyl-4-chloro-N-cyclohexylbenzamide 
HMGB1 high mobility group box-protein 1 
PBS  phosphate buffered saline 
PKC  protein kinase C 
PVDF  polyvinylidene difluoride 
RAGE  receptor for advanced glycation end products 
rh  recombinant human 
SDS-PAGE sodium dodecyl sulphate- polyacrylamide gel electrophoresis 
STZ  streptozotocin 
TRP  transient receptor potential 
VEGF-A vascular endothelial growth factor-A 
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Diabetic neuropathy affects up to 50% of diabetic patients (Obrosova, 2009) 
and results from changes in the peripheral sensory nerve microenvironment 
due to microvasculopathy, and direct actions of high glucose on peripheral 
sensory neurons. Sensory neurons are particularly susceptible to 
hyperglycaemic damage as they lack insulin-regulated glucose uptake 
(Tomlinson and Gardiner, 2008). Peripheral sensory fibre damage in nerve 
trunks results in local inflammatory responses and the development of 
neuropathic pain including symptoms of allodynia and hyperalgesia in 
experimental and naturally occurring diabetes (Calcutt et al., 2008).  
 
Long-standing hyperglycaemia results in the formation and accumulation of 
advanced glycation end products (AGEs) (Singh et al., 2014), which can 
activate the receptor for AGE (RAGE) and cause neuronal damage. Other 
RAGE ligands, such as the inflammatory cytokine high mobility group box-
protein 1 (HMGB1, a.k.a. amphoterin), can act more rapidly to activate RAGE 
(Saleh et al., 2013), and may contribute to pain through modulation of neuro-
inflammatory responses (Maeda et al., 2013). RAGE expression is increased 
in peripheral neurons in traumatic (Allette et al., 2014) and diabetic 
neuropathy (Juranek et al., 2013), and RAGE neutralisation inhibits 
neuropathic pain (Brederson et al., 2016). The mechanism(s) of RAGE 
signalling on sensory neuronal sensitisation are unknown.  
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
  
HMGB1 levels are increased in plasma in diabetic patients (Devaraj et al., 
2009) and HMGB1 is implicated in chronic pain (Agalave and Svensson, 
2015) associated with arthritis (Ke et al., 2015), and traumatic (Allette et al., 
2014; Feldman et al., 2012; Nakamura et al., 2013) and chemotherapy-
induced neuropathic pain (Nishida et al., 2016), probably through RAGE 
activation (Allette et al., 2014). HMGB1 sensitises and activates sensory 
neurones in a manner that would lead to altered nociceptive behaviour 
(Feldman et al., 2012), but the mechanism through which these changes 
occur are unknown.  
 
TRP channels such as TRPA1 and TRPV1 are implicated in both the pain 
(Cui et al., 2014; Pabbidi et al., 2008; Wei et al., 2009) and neuronal damage 
in diabetic neuropathy (Koivisto et al., 2012). The pain and neuronal damage 
in diabetic neuropathy are related to the decrease in expression of vascular 
endothelial growth factor-A (VEGF-A) (Jeric et al., 2017; Pawson et al., 2010), 
a family of growth factors with effects on both vascular and neuronal systems 
(Carmeliet and Storkebaum, 2002). We showed that pain and neuronal 
activation associated with one VEGF-A splice variant, VEGF-A165a, are 
mediated through effects on TRPV1 (Hulse et al., 2014). These effects can be 
reversed by the alternatively spliced VEGF-A165b isoform (Harper and Bates, 
2008), which also decreases neuropathic pain behaviours in diabetic rats 
(Hulse et al., 2015).  
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In these studies we tested the hypotheses that: 
1. Hyperglycaemia is associated with increased peripheral HMGB1 
expression in diabetic rats when mechanical and thermal hypersensitivity is 
present;  
2. HMGB1 sensitises neurons through actions on TRPV1;  
3. High glucose conditions alter TRPV1-mediated signalling in sensory 
neurons through an HMGB1/RAGE/PKC-dependent mechanism, and  
4. That the effects of HMGB1 on sensory neurons can be reversed by VEGF-
A165b treatment.  
 
 
Results  
STZ induced hyperglycaemia that, with low dose insulin treatment, was stable 
and sustained over at least 7 weeks, with little weight loss in the animals 
(Hulse et al., 2015). Weight loss was not observed in these animals over the 3 
weeks of the study (see below). At three weeks animals showed significant 
thermal and mechanical hypersensitivity in the hind paws, which was 
ameliorated by systemic VEGF-A165b treatment (Figure 1), consistent with 
published data (Hulse et al., 2015). As previously reported, VEGF-A165b 
treatment had no effect on animal weight or blood glucose levels (Weights 
after 3 weeks of treatment: naives 289 ± 7 (mean±SEM), diabetes + vehicle 
261 ± 6g, diabetes + VEGF-A165b 264 ± 4g. Blood glucose levels: naives 6 ± 
0.2mM/L, STZ + vehicle 27 ± 1nM/L, STZ + VEGF-A165b 29 ± 0.8mM/L. 
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 Animal weight and glucose levels at 7 weeks as previously published (Hulse 
et al., 2015)). 
 
HMGB1 and RAGE expression is increased in STZ diabetic rats  
HMGB1 protein expression was significantly increased in hind paw plantar 
skin at both 3 and 7 weeks post STZ injection. The change in expression of 
HMGB1 was not affected by treatment with VEGF-A165b (Figure 1). We 
confirmed RAGE expression in dorsal root ganglion (DRG), which contains 
the cell bodies of somatosensory neurons (Figure 2A). RAGE expression was 
seen in the majority of DRG neurons, across the whole range of cell sizes, 
and changes in diabetes were not limited to a particular subgroup of neurons 
(data not shown). RAGE expression is in a positive feedback mechanism with 
RAGE activation and therefore we determined whether there was any change 
in RAGE expression in sensory neurons in diabetic rats. The proportion of 
DRG neurons positive for RAGE expression was increased in diabetic rats 
compared to naïve, as previously reported (Zochodne, 2014), and this was 
unaffected by VEGF-A165b treatment (Figure 2B). The intensity of the RAGE 
staining in individual RAGE positive DRG neurons was also increased in 
diabetic rats compared to naïve, and this increase was partially ameliorated 
by VEGF-A165b (Figure 2).  
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Enhanced TRPV1-evoked calcium responses in STZ diabetic rats DRG 
neurons is a hyperglycaemia-mediated event and is prevented by VEGF-
A165b treatment.  
TRPV1 contributes to primary sensory neuronal sensitisation in many pain 
states (Marwaha et al., 2016), including diabetes (Cui et al., 2014; Pabbidi et 
al., 2008), and the degree of behavioural hypersensitivity is associated with 
increased agonist-evoked TRPV1 activity. We therefore determined whether 
DRG neurons isolated from diabetic rats showed increased TRPV1 agonist-
evoked calcium responses. Capsaicin evoked a larger response in DRG 
neurons from female diabetic rats compared to DRG neurons from naïve 
female rats (Figure 3A). This effect could be modelled in DRG neurons from 
adult naïve male rats exposed to 24h of high glucose (50mM glucose), with an 
increased intracellular calcium fluorescence response to 1µM capsaicin 
compared to basal glucose conditions (Figure 3B). This demonstrates that the 
enhanced TRPV1-evoked calcium responses were, at least in part, a 
hyperglycaemia-induced effect. The inclusion of equimolar mannitol in the 
basal glucose condition indicates that effects of 50mM glucose cannot be 
attributed to any osmotic effect of the additional glucose. The specific TRPV1 
antagonist capsazepine blocked the capsaicin (Cap)-evoked change in 
intracellular calcium in primary sensory neurons in this assay, in a 
concentration-dependent manner (Figure 3C), with an IC50 of ~1µM.  
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High glucose-mediated increased TRPV1-evoked calcium responses were 
significantly reduced when DRG neurons were co-treated with VEGF-A165b in 
high glucose conditions (Figure 4). TRPV1 sensitisation, which leads to 
increased calcium influx, has previously been attributed to increased 
phosphorylation, particularly at serine 800 (Mandadi et al., 2006; Wang et al., 
2015), which is a PKC-dependent phosphorylation site. In immortalised 
embryonic rodent DRG neurons (50B11) exposed to high glucose conditions 
phosphorylation of TRPV1 at S800 increased compared to basal glucose 
conditions, with no effect on total TRPV1 expression ((Radu et al., 2013), see 
also (Khomula et al., 2013; Mohammadi-Farani et al., 2014)). Both high-
glucose-enhanced TRPV1 calcium responses (Figure 4A, B) and TRPV1 
phosphorylation (Figure 4C-D) were reduced after 24h exposure to VEGF-
A165b, even though TRPV1 expression was slightly increased by VEGF-A165b 
treatment (Figure 4E).  
 
Increased RAGE activity contributes to high glucose-induced TRPV1-
evoked calcium responses in DRG neurons  
As the RAGE agonist HMGB1 was increased in the skin (i.e. in the tissues 
surrounding nociceptive neuronal terminals) of diabetic animals, we 
hypothesised that the altered neuronal sensitivity to TRPV1 agonists seen in 
vitro could be RAGE-dependent. The RAGE antagonist FPSZM1 did not 
affect capsaicin-evoked TRPV1 calcium changes in normal glucose 
concentrations (Figure 5A), but reduced calcium fluorescence in high glucose 
conditions in a concentration-dependent manner (Figure 5B). Concentrations 
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 of FPSZM1 above 10nM reduced capsaicin-evoked calcium responses to 
control levels (Figure 5C).  
 
HMGB1 increases TRPV1-agonist-evoked calcium responses, and is a 
RAGE mediated effect that is blocked with VEGF-A165b 
HMGB1 is a RAGE agonist that has been implicated in peripheral nociceptive 
signalling (Feldman et al., 2012).  HMGB1 increased capsaicin-evoked 
TRPV1 calcium responses in DRG neurons (10mM glucose; Figure 5D) and 
this was reduced by incubation with 10nM FPSZM1 (Figure 5E). Inhibition of 
PKC activity by incubation of DRG neurons with HMGB1 and 1µM BIM-1 
reduced capsaicin-evoked TRPV1 calcium changes (Figure 6A). HMGB1-
enhanced TRPV1-evoked calcium responses were also reduced following 24h 
treatment with VEGF-A165b (Figure 6B).  
Effect sizes for data in all experiments are shown in Table S1.  
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Discussion 
 
These data collectively show for the first time that, in vitro, 1) high glucose 
concentrations alter TRPV1-evoked calcium responses in DRG neurons 
through RAGE; 2) HMGB1 alters TRPV1-evoked calcium responses through 
RAGE in DRG neurons under basal glucose conditions, which is PKC 
dependent, and blocked by VEGF-A165b, and 3) HMGB1 is up-regulated in 
skin in diabetic rats. This is the first study to demonstrate a potential neuronal 
mechanism through which HMBG-1/RAGE could alter DRG neuronal 
properties under high glucose conditions in vitro.   
 
There have been many proposed causes for painful diabetic neuropathy. 
These include microvasculopathic neuronal hypoxia, direct effects of glucose 
toxicity on sensory neurons, and activation of TRPA1 and other ion channels 
in sensory neurons by reactive metabolites such as methylglyoxal (Andersson 
et al., 2013; Huang et al., 2016). In the later stages of the condition, RAGE 
activation by AGEs is driven by molecules such as methylglyoxal, resulting in 
cellular damage, and further complications (Hidmark et al., 2014). RAGE is a 
pattern recognition receptor that is capable of signalling local tissue damage 
(Kato et al., 2016). Activation of RAGE by AGEs usually results after 
significant accumulation of AGEs over time (months to years in vivo), and is 
considered to be a late contributor to diabetic complications (Singh et al., 
2014). Herein we show that neuronal RAGE activity in sensory neurons is not 
detectable in neurons cultured in normal glucose concentrations, but is 
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 evident following a short (24h) exposure to high glucose (50mM) in vitro. AGE 
formation is reported to occur after 6-10 days in 2M glucose in vitro (Hori et 
al., 2012), suggesting that our experimental conditions would not be sufficient 
to cause AGE generation. Thus, we hypothesise that neuronal RAGE 
activation after short exposure to high glucose, possibly through the more 
rapid generation of HMGB1, could contribute to early changes in neuronal 
properties, resulting in enhanced nociception.  
 
Importantly the endogenous RAGE agonist HMGB1 itself alters TRPV1-
evoked neuronal responses under normal glucose conditions. HMBG1 has 
been found in Schwann cells, DRG satellite cells and primary sensory 
neurons in traumatic neuropathy (Wan et al., 2016), in sensory neurons in 
experimental diabetes (Juranek et al., 2013), and human diabetic nerve 
(Bierhaus et al., 2004). HMGB1 has been implicated in peripheral 
mechanisms of pain through both direct (Allette et al., 2014) and indirect 
activation of sensory neurons through interaction with pro-inflammatory 
molecules such as IL-1 and TNF (Wan et al., 2016), and RAGE-mediated 
pro-inflammatory cytokine release from immune cells (Kato et al., 2016). 
Taken together, our data support a direct effect of HMGB1 on sensory 
neurons, with rapid (≤24h) onset, that can be induced under high glucose 
conditions in vitro, extending our understanding of the function of HMGB1 and 
its effects on functional neuronal change. As the RAGE agonist HMGB1 is 
increased in skin in diabetic rats when pain behaviour is altered (data herein 
(Hulse et al., 2015)), and RAGE expression is increased in sensory neurons 
(Zochodne, 2014), these peripheral actions of HMGB1 may be a contributory 
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 factor in the pain associated with glucose-induced neuronal damage and pain 
in diabetes.  
 
Modulation of the TRP channels TRPA1 and TRPV1 has been implicated in 
both neuronal damage and pain in diabetic neuropathy (Cui et al., 2014; Hong 
and Wiley, 2005; Khomula et al., 2013). TRPA1 and TRPV1 are important 
molecules in the sensitisation of peripheral nociceptive afferents (Cheng and 
Ji, 2008), and TRPV1 is directly sensitised by high glucose conditions in 
sensory neurons (Lam et al., 2018) and in diabetes in vivo (Hong and Wiley, 
2005; Khomula et al., 2013). TRPV1 phosphorylation by PKC at serine-800 is 
key to its sensitisation (Wang et al., 2015). Both S800-TRPV1 
phosphorylation and sensitisation can be increased in high glucose conditions 
in vitro, and by RAGE activation by HMGB1. TRPV1 is phosphorylated and 
sensitised by a PKC-dependent mechanism in diabetes in vivo (Hong and 
Wiley, 2005). RAGE-PKC interactions can also modulate neuronal function in 
vivo, affecting conduction velocity slowing (indicative of peripheral neuronal 
damage), as well as neuronal repair in diabetic neuropathy (Zochodne, 2014). 
While other signalling pathways, such as PKA, are also known to contribute to 
sensory neuronal sensitisation (Cheng and Ji, 2008), our data are consistent 
with PKC-mediated phosphorylation of sensory neuronal TRPV1 being one 
important mechanism through which HMGB1, and presumably other RAGE 
agonists, could rapidly sensitise peripheral neurons. This could contribute to 
pain in conditions where HMGB-1 is expressed, such as various neuropathic 
conditions (Allette et al., 2014; Brederson et al., 2016; Juranek et al., 2013).  
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 While TRPV1 expression changes were reported in specific DRG neuronal 
subpopulations, total TRPV1 levels were reported to decrease in DRG in 
diabetic rats (Hong and Wiley, 2005). Despite this overall decrease in TRPV1 
expression, neuronal TRPV1 functional responses were increased 
(sensitised) through a PKC-dependent mechanism (Hong and Wiley, 2005). 
This agrees with our findings under high glucose conditions in vitro and 
suggests that our reported differences between naïve and diabetic DRG 
calcium responses ex vivo are not attributable to alteration in TRPV1 
expression levels alone. We found no change in neuronal TRPV1 expression 
in high glucose conditions (Fig. 4).  It should also be noted that in measuring 
intracellular calcium levels, albeit evoked by a TRPV1 agonist, the enhanced 
responses we report might represent TRPV1 sensitisation in vitro and ex vivo, 
but could also be attributable to changes in other ion channels. RAGE can 
directly contribute to PKC-dependent capsaicin-induced non-TRPV1-mediated 
intracellular calcium increases in high glucose conditions (Lam et al., 2018). 
TRPA1 is also sensitised in rat DRG immortalised neurons (50B11) in high 
glucose conditions in vitro (Hulse et al., 2015) and in animal models of 
diabetes. TRPA1 forms complexes with TRPV1, and can affect TRPV1 
function, such as reducing desensitisation, thus potentially altering calcium 
responses (Masuoka et al., 2017; Staruschenko et al., 2010). There is, 
however, no evidence that RAGE can directly alter TRPA1 function. Voltage-
gated sodium and calcium channels are also involved in diabetic pain in STZ 
rodents, for example through methylglyoxal-RAGE-mediated effects on 
Nav1.8 (Huang et al., 2016), TNF-NFB-mediated upregulation of Nav1.7 
(Huang et al., 2014), or upregulation of calcium channel subunits (Yusaf et al., 
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 2001). All of these effects will contribute to the known changes in nociceptor 
properties in diabetes in vivo (Chen and Levine, 2001), and could also 
contribute to the in vitro changes that we report.   
 
Hypoxia, known to affect peripheral tissues including nerves, is a potent 
stimulus for TRPV1 sensitisation through hypoxia-inducible factor (HIF) -1 
alpha and PKC (Ristoiu et al., 2011). Hypoxia and HIF-1 also induce 
expression of the pro-nociceptive VEGF-A isoform VEGF-A165a, which also 
sensitises TRPV1 through PKC (Hulse et al., 2014). We have previously 
shown that bi-weekly treatment with rhVEGF-A165b reverses both pain and 
neuronal terminal loss in experimental diabetes, and sensitisation of sensory 
neuronal TRPA1-evoked responses (Hulse et al., 2015). Given that RAGE 
expression is up-regulated by HMGB1, the reduction in RAGE intensity in vivo 
by VEGF-A165b treatment (Fig. 3C) suggests that this treatment could reduce 
HMGB1 activation of RAGE, or modify the downstream signalling from 
HMGB1/RAGE activation that results in the feed-forward agonist-induced up-
regulation of RAGE, resulting in reduced pain, rather than exerting direct 
effects on neuronal TRPV1. This requires confirmation, as does the 
contribution of HMGB1/RAGE/TRPV1 to altered pain behaviour in diabetic 
neuropathy in vivo. Blockade of HMGB1/RAGE-mediated neuronal 
sensitisation by rhVEGF-A165b in vitro supports our hypothesis that alteration 
of VEGF-A isoforms, for example by treatment with rhVEGF-A165b or an agent 
that alters VEGF-A splicing to favour VEGF-A165b may be an effective 
treatment for diabetic neuropathy.   
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 Materials and methods  
 
Cell culture reagents (media and media supplements) and equipment were 
supplied by Invitrogen Life Technologies (Paisley, UK). Protein extraction 
buffer, supplements, buffers, and solutions, streptozotocin and sodium 
pentobarbital were supplied by Sigma-Aldrich (Irvine, UK) and Western blot 
reagents and equipment through Bio-Rad (CA, USA). Superfrost plus slides 
and OCT embedding medium were supplied by VWR International, (PA, USA) 
and DAPI by Vector laboratories, (Peterborough, UK). Behavioural testing 
equipment was supplied by Ugo Basile (Varese Italy).  
Drugs were supplied by R&D Systems (MA, USA) (rhVEGF-A165b and 
rhHMGB1), EMD Millipore (MA, USA) (FPSZM1) and LinShin (insulin pellets). 
Details of antibodies and sources are shown in Table 1.  
 
 
A total of 63 male and female rats (Charles River Laboratories, Kent, UK) 
were used in this study. All experiments were carried out in laboratories at the 
University of Nottingham in accordance with the EU 2010/63 Directive, the 
United Kingdom’s Scientific Procedures Act 1986 and associated 
amendments and guidelines (2012) and were approved by the University of 
Nottingham AWERB (Animal Welfare and Ethical Review Board). The 
experiments in these studies conformed to the principles of the ARRIVE 
guidelines. Animals were housed at 21oC and 55% relative humidity with a 
12h light-dark cycle. For diabetic animals food and water were provided ad 
libitum except immediately prior to STZ injection.  
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Humane endpoints included loss of body weight >15%; animal behaviour 
indicative of pain or distress, such as staring coat, immobility, hunched stance 
(no animals met any of these endpoints). All rats were group housed 
(minimum 2 animals per cage) under 12 hour light-dark cycles, with additional 
paper bedding material and environmental enrichment, ad libitum access to 
standard chow and water. Due to increased urination in diabetic animals, 
bedding and cage materials were changed frequently, usually at need rather 
than at specific time intervals.  
Adult female Sprague Dawley rats (~250g, n=35) were used in the in vivo 
diabetes study. Adult female Sprague Dawley rats were used for STZ-
diabetes as these animals reach the top of their growth curve at about this 
age. It is therefore easier to monitor animal welfare, as even small amounts of 
weight loss in comparison to untreated control animals is evident with 
correction for any growth-related weight gain (Calcutt, 2004). Adult male 
Wistar rats (~250-350g, n=29) were used for primary dorsal root ganglion 
neuronal cultures in vitro, as previously reported (Hulse et al., 2014; Hulse et 
al., 2015).  
Animal numbers were determined a priori based on effect sizes in multiple 
measures derived from a previous group of animals that underwent the same 
procedures in a previous study using G*Power (Faul et al., 2007; Hulse et al., 
2015) 
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Diabetes was induced with an intraperitoneal injection (i.p.) of streptozotocin 
(STZ; 50mg.kg-1) as previously described (Hulse et al., 2015). 
Hyperglycaemia (>15mM circulating glucose) was confirmed 4 days after STZ 
injection; in animals in which hyperglycaemia was not confirmed after initial 
STZ injection, a second STZ injection was administered. Animals in which 
STZ injection did not result in hyperglycaemia (n=6) were not used in further 
experiments. STZ-injected hyperglycaemic animals were treated with very low 
dose insulin supplementation with 1/3 of a LinShin insulin pellet injected 
subcutaneously in the scruff of the neck under brief general isofluorane 
anaesthesia (2-3% in O2), and using the sterile trocar supplied by the 
manufacturer (Calcutt, 2004; Hulse et al., 2015). Animals were supplied with 
concentrated sucrose solution to reduce the incidence of hypoglycaemia in 
the 24h immediately post-STZ injection (Calcutt, 2004). Experimental groups 
were: diabetic rats treated bi-weekly with recombinant human (rh)VEGF-A165b 
injection (20ng.g-1 body weight, n=9) or phosphate buffered saline (PBS, 
VEGF vehicle, n=9) (Hulse et al., 2015). Age matched naïve rats (n=11) 
served as non-diabetic controls. Bi-weekly injections of VEGF-A165b and PBS 
began 1 week after confirmation of both hyperglycaemia and altered 
nociceptive behaviour, a treatment regime we have previously shown to be 
effective in traumatic and diabetic neuropathies (Hulse et al., 2014; Hulse et 
al., 2015). Animals were maintained for a further 3 weeks after confirmation of 
hyperglycaemia. Weekly thermal and mechanical nociceptive testing was 
performed throughout the duration of the study.  
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Rats were habituated to nociceptive behavioural testing environments for 2 
weeks prior to STZ injection and for 20 minutes before the start of each 
weekly session. Thermal nociceptive testing was performed using the 
Hargreaves test (Hargreaves et al., 1988). The intensity of the radiant heat 
source was set so that the mean response latency was ~10s in naïve animals 
at baseline testing and the intensity was kept constant throughout the duration 
of the study. Three latencies were measured in each testing session and the 
mean value calculated. To prevent heat induced tissue damage an inter-
stimulus interval of a minimum of 5 minutes was used between 
measurements. Mechanical nociceptive testing was performed using von 
(v)Frey monofilaments as previously described (Hulse et al., 2014; Hulse et 
al., 2015). vFrey monofilaments of varying force were applied to the plantar 
surface of the hind paw 5 times each to generate a stimulus-response curve 
and the withdrawal threshold (force in grams) was calculated as the force at 
which the animal withdrew to 50% of stimulus presentations. For both thermal 
and mechanical testing, measurements were taken for both left and right hind 
paws and the data were treated as duplicates for each animal. The animal 
was taken as the independent observation not the paw. The operator 
performing behavioural testing was blinded to the treatment groups as 
another researcher coded the injections for treatments. As the operator 
administering the injections was blinded, this resulted in a randomisation of 
treatment order.  
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After 3 weeks, rats were terminally anesthetized (sodium pentobarbital 
60mg.kg-1, i.p.) and transcardially perfused with PBS. Plantar skin and L3/4/5 
DRG were dissected and a) immediately snap frozen on dry ice and then 
transferred to -80°C before processing for protein extraction or b) DRG were 
dissected and post-fixed for 24h in 4% paraformaldehyde (PFA, pH 7.4) at 
4°C and then transferred to 30% sucrose solution for a further 24 h at 4°C for 
immunofluorescence.  
In vitro assessment of TRPV1 expression and phosphorylation.  
50B11 neurons (a gift from Ahmed Hoke, provided through Damon Lowes, 
see Acknowledgements) are an immortalized dorsal root ganglion sensory 
neuronal cell line derived from embryonic rats (Chen et al., 2007) and were 
used as a model system to determine changes in total TRPV1 and 
phosphorylated TRPV1 under different glucose conditions, and to reduce the 
numbers of animal numbers used. These cells were authenticated in house as 
expressing functional neuronal markers, particularly those associated with 
nociception such as TRPA1 and TRPV1(Bestall, 2017). 50B11s were 
maintained in neurobasal media supplemented with 10% foetal bovine serum, 
0.55mM glutamine, B27 supplement and an additional 11mM glucose (making 
the total glucose concentration 36mM (Chen et al., 2007)). Basal glucose 
concentration is thus higher for 50B11 maintenance than for primary sensory 
neurons, but is required for their culture. 50B11 neurons have impaired 
neurite outgrowth in both normal (5mM) and high (66mM) glucose conditions 
(Bestall, 2017).  
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50B11 neurons were differentiated for 24h with 1nM nerve growth factor 
(NGF) and 75µM forskolin and then treated for a further 24h under the 
following conditions: basal glucose (36mM glucose + 30mM mannitol), high 
glucose (66mM glucose) ± recombinant human VEGF-A165b (2.5nM) or PBS 
(VEGF vehicle). After 24h, protein was extracted and subject to Western 
blotting for TRPV1 and phospho-serine 800-(p800)TRPV1. Equimolar 
mannitol addition controlled for any potential effect of increased osmolarity 
under high glucose conditions.   
 
Western blotting.  
Protein was extracted in RIPA buffer containing 150mM sodium chloride, 1% 
nonyl phenoxypolyethoxylethanol (NP-40), 0.5% sodium deoxycholate, 0.1% 
SDS, and 50mM Tris (pH 8.0) supplemented with protease inhibitor cocktail 
(20µl.ml-1 buffer; 1mM phenylmethylsulfonyl fluoride, 10mM sodium 
orthovanadate and 50mM sodium fluoride). Equal amounts of protein were 
loaded and separated on a 4-20% gradient precast SDS-PAGE gel and 
proteins transferred to a PVDF membrane using wet transfer. Membranes 
were incubated in blocking buffer (5% bovine serum album in Tris buffered 
saline containing 0.1% Tween 20) for 60 minutes at room temperature and 
incubated overnight at 4°C in primary antibodies against TRPV1, p800-
TRPV1, and HMGB1 (Table 1) diluted in blocking solution. Loading was 
confirmed and differences determined by concurrent probing for actin 
expression. Membranes were then washed in PBS and fluorescent secondary 
antibodies (Table 1) were applied in blocking solution for 60 minutes at room 
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 temperature. Membrane fluorescence was visualized and analysed on a Licor 
Odyssey Fc. 
 
Immunofluorescence 
Following fixation and cryoprotection of tissue from diabetic rats, DRG were 
embedded and frozen at -80°C before sectioning at 8µm thickness. Sections 
were then stored mounted on slides (Superfrost plus) at -80°C.  Sections were 
washed in PBS, blocked with 5% bovine serum albumin, 10% foetal bovine 
serum in PBS + 0.2% Triton X-100). Sections were incubated in primary 
antibodies against RAGE and NeuN (Table 1) in blocking solution overnight at 
4°C. Slides were washed in PBS and incubated in fluorescent secondary 
antibodies in PBS-0.2% Triton X100 for 2 h at room temperature, then 
coverslipped with Vectorshield mounting media containing DAPI (4',6-
diamidino-2-phenylindole). A minimum of 5 randomly selected non-serial 
images were acquired from at least 5 sections from each animal per treatment 
group at 20x magnification using consistent microscope settings between 
channels on a Leica TCS SPE confocal microscope and the Leica 
applications suite software (LAS X). All immunofluorescence images were 
equally enhanced (30% increase in brightness, 0% change in contrast) for 
presentation (Figure 3). Images were exported for further analysis in Image J 
software (specifically FIJI)(Schindelin et al., 2012). The number of RAGE 
positive neurons was determined by counting the number of NeuN positive 
DRG neurons that co-expressed RAGE. RAGE intensity analysis was 
performed using the mean grey area values for these neurons. For each 
image containing RAGE positive neurons, a local mean grey area background 
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 value was subtracted from experimental values.  All image analysis was 
performed blinded to treatment group on raw images. The images shown 
(Figure 2) are altered for brightness (+35%) and contrast (-20%) compared to 
the raw images used for analysis. The RAGE antibody (Table 1) detected a 
single band of ~45kD as expected, in 50B11 neurons (Figure S1).  
 
TRPV1 activity in vitro.  
For primary sensory neuronal culture, widely used to study mechanisms of 
neuronal signalling and sensitisation using single cell approaches (Huang et 
al., 2015) through to high throughput screening (Hulse et al., 2014; Newberry 
et al., 2016), adult male Wistar rats were killed by anaesthetic overdose 
(60mgkg-1 sodium pentobarbital, i.p. injection) and death verified by 
confirmation of cessation of the circulation.  
T1-L6 DRGs were dissected, enzymatically and mechanically dissociated, 
and cultured on poly-L-lysine/ laminin coated 96 well plates (black sided, 
Costar) at a seeding density of 2000 cells per well in Ham’s F12 medium 
containing 1x N2 supplement 1% BSA and 1% penicillin streptomycin. Equal 
numbers of cells were seeded per well to reduce the inter- and intra-assay 
variability between wells. After cell attachment, cultures were treated with 
30µg.ml-1 5-fluoro-2’-deoxyuridine to prevent mitosis of non-neuronal cells. 
Neuronal cultures were maintained in basal glucose conditions (10mM 
glucose +40mM mannitol as an osmotic control) or high glucose conditions 
(50mM glucose) for 24h +/- the following co- treatments: 2.5nM rhVEGF-
A165b; rhHMGB1 (1-100nM); FPSZM1 (RAGE antagonist 1-100nM), and 1µM 
BIM-1 (PKC inhibitor). Cells were then loaded with Fluo-4 (Invitrogen) in 
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 Hank’s balanced buffered saline solution containing 20mM HEPES and 2mM 
CaCl2 for 1 hour. The TRPV1 agonist capsaicin (1µM unless otherwise stated, 
concentration chosen based on previous findings (Hulse et al., 2014) known 
to be in the range for agonist-specific TRPV1-evoked responses (Edwards, 
2014)) was used to stimulate TRPV1 channels and the resulting changes in 
intracellular calcium fluorescence were measured on a Victor X4 plate reader 
at 37°C over a 160 second period. In some experiments, to verify the calcium 
response as being evoked through activation of TRPV1, primary neuronal 
cultures were dissociated, plated and maintained in basal glucose for 24 h. 
Following loading with Fluo-4, capsazepine or vehicle (0.03% DMSO) was 
added to the culture 20 minutes prior to addition of 1µM capsaicin and 
calcium assay. In all assays baseline readings were determined prior to initial 
capsaicin application and under control conditions to determine any 
background signal. The sequential fluorescence recordings were corrected for 
background, and expressed as a fold change of respective baseline values to 
reduce inter-well variance and to control for minor variations in cell number 
(Hulse et al., 2014). The inter-assay mean coefficient of variation was 8.9% 
(from n=11 independent experiments, each containing 3-20 repeats all 
performed by SMB). Fluorometric imaging plate assays such as this are 
widely used to assay TRPV1 responses to capsaicin in transfected and native 
cells; responses are known to be TRPV1-dependent (Gunthorpe et al., 2007; 
Pineau et al., 1996; Rami et al., 2006; Tafesse et al., 2004; Wang et al., 2014; 
Zhuang et al., 2004). Each plate contained DRG neurons from a single rat 
and in each replicate plate cells were exposed to the same combination of 
experimental treatment conditions in a block design, to allow comparison of 
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 responses within and between plates. For reproducibility each assay was 
performed multiple times as noted in the text, and each independent plate 
was exposed to identical treatments in each experiment. Calcium levels were 
normalised to baseline measures in each plate to allow for pooling of data 
derived from replicates, as is usual with repeated high throughput assays 
(Iversen et al., 2004).  
This assay uses TRPV1 as a read-out for altered nociceptive neuronal 
activity, and thus these experiments were not designed to investigate precise 
mechanisms of TRPV1 modulation. We have previously validated this high-
throughput assay for its ability to replicate the effects of compounds assayed 
by single cell patch clamp analysis (Hulse et al., 2014). The use and 
comparison of capsaicin-evoked calcium responses in each assay limits the 
comparisons being made to the responses of the TRPV1-expressing 
nociceptive population of sensory neurons in the rat, ensuring comparison of 
like responses between assays. The TRPV1-expressing population 
represents ~65% of DRG nociceptors (peptidergic + IB4+ populations (Price 
and Flores, 2007).  
 
Experimental design, data extraction and analysis  
Effect sizes and representative data values for experiments in this manuscript 
are given in the Supplementary Information (Table S1). TRPV1 activity assay 
sample size calculations were determined using previously published data 
(Hulse et al., 2014; Hulse et al., 2015) and the following parameters: repeated 
measures ANOVA, between factor, power 0.8, number of groups 3, number of 
measurements per group, 21. Sample size calculation for behavioural 
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 experiments was based on a two tailed non-parametric analysis (Mann 
Whitney), minimum required power 0.8. Numbers of animals used were 
calculated to give sufficient power for further tissue analyses on subgroups 
given the possibility for tissue loss and small tissue samples (DRG).  
All data are presented as mean ±SEM and n values given represent 
independent observations, which are usually individual animals or 
independent cultures/treatments. Multiple group comparisons were made by 
one-way ANOVA (treatment effects), Kruskal-Wallis (KW, treatment effects) or 
two-way ANOVA (treatment effects over time, or with agonist concentration), 
all two tailed tests, as stated in Figure legends. Overall effects of different 
condition effects on neuronal calcium over time were compared by 
comparison of integrated area under the curve for each independent assay 
followed by comparison using parametric/non-parametric ANOVA as stated in 
Figure legends. For concentration:response curves (Figures 4 & 6), each 
individual data point comprises of the mean AUC, rather than peak calcium 
response, from the stated number of experimental repeats. Pair wise post-hoc 
comparisons were made using Sidak’s tests or Dunn’s tests as stated in 
Figure legends, with correction for multiple comparisons, when ANOVA 
significance was reached. Alpha was set at 0.05. All statistical analysis was 
performed using GraphPad Prism v6-7 for Windows and Mac, (GraphPad 
Software, La Jolla California USA, www.graphpad.com). 
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Figures 
 
 
 
Figure 1. Effect of VEGF-A165b on thermal and mechanical 
hypersensitivity in STZ-diabetic rats. A. STZ-induced thermal 
hypersensitivity was evident at 3 weeks after STZ injection, and was 
prevented with systemic VEGF-A165b (2 way ANOVA, treatment: 
F(2,103)=17.26, p= <0.0001; time: F(3,103)=3.74, p=0.013; interaction: 
F(6,103)=2.59, p = 0.022. *p<0.05 post hoc Sidak’s test). B. STZ-induced 
mechanical hypersensitivity, measured by a reduction in 50% withdrawal 
thresholds, and was prevented with VEGF-A165b by week 3. (2 way ANOVA, 
treatment: F(2,104)=6.744, p=0.0018; , time: F(3,104)=8.337,p=<0.0001; 
interaction: F(6,104)=3.03, p=0.009. *p<0.05 post hoc Sidak’s test). Arrows 
indicate STZ injection and the dotted line the start of bi-weekly systemic 
rhVEGF-A165b or vehicle treatment. Data shown are mean ± SEM, naïve n=11 
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 STZ + PBS n=9 STZ + VEGF-A165b n=9. C. Representative Western blots of 
HMGB1 and actin in hind paw plantar skin at 3 and 7 weeks after STZ 
injection.  D. HMGB1 protein expression was increased in skin from diabetic 
rats at both 3 (Kruskal-Wallis statistic 7.367, p=0.0132) and (E) 7 weeks (one 
way ANOVA F(2,12) =15.31, p=0.0005). The change in HMGB1 was not 
altered with VEGF-A165b treatment. Plots show mean ± SEM and individual 
data points, n=5 (naïve at both 3 and 7 weeks, STZ 7 weeks), n=4 (STZ, 3 
weeks. * p<0.05, n.s. not significant, post=hoc Dunn’s (3 weeks) and Sidak’s 
tests (7 weeks)). 
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Figure 2. RAGE is expressed in normal DRG neurons and is increased in 
STZ diabetic rats.  
A. Representative images of RAGE (green) and NeuN (neuronal marker, red) 
staining, showing RAGE expression in DRG neurons in naïve and diabetic 
rats. B. The percentage of the total neurons in the DRG expressing RAGE 
increased in diabetic rats, and this was not affected by VEGF-A165b treatment 
(one way ANOVA F(2,7)=9.104, p=0.0113). C. RAGE intensity per neuron 
was increased in diabetic rats, and this increase was partially prevented by 
VEGF-A165b treatment (one way ANOVA F(2,7)=28.37, p=0.0004,). Plots 
show mean ± SEM and individual data points, n= 4 (naïve) and 3 (all STZ 
groups). *p<0.05, ***p<0.001, n.s. = not significant, ANOVA + post-hoc 
Sidak’s test.  
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Figure 3. STZ diabetes in vivo, and high glucose conditions in vitro, 
increase TRPV1 activity to agonist in DRG neurons. A. Capsaicin evoked 
TRPV1 activity was greater in DRG neurons from diabetic rats (n=3) 3 weeks 
after STZ injection compared to DRG from naïve rats (n=4) (2 way ANOVA: 
interaction F(5,28)=2.86, p=0.03; capsaicin concentration F(5,28)=8.45, 
p<0.0001; STZ/naïve F(1,28)=29.19, p<0.0001. *p<0.05 post hoc Sidak’s 
test). B. Capsaicin-evoked TRPV1 activity was also enhanced in naïve DRG 
neurons exposed to 24 h of 50mM glucose (n=5) compared to 10mM glucose 
for 24h (n=5, data shown are mean ± SEM, two way ANOVA interaction 
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 F(5,149)=2.742, p=0.02; glucose concentration F(1,149)=2.45, p=0.12; 
capsaicin concentration F(2, 149)=8.16, p<0.0001) **p<0.01 post hoc Sidak’s 
test. C. Capsaicin-evoked increase in intracellular calcium is blocked by 
TRPV1 antagonist capsazepine (n=7 replicates. (1µM Cap), 5 (1µM Cap + 
5µM CPZ), and 8 (1µM Cap + 10 & 20µM CPZ. Neurons derived from 3 rats). 
Values are normalized to the maximum response evoked in the control 
conditions for each experiment (indicated by horizontal dashed line in A & B). 
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Figure 4. VEGF-A165b blocks high glucose-mediated TRPV1 sensitization 
and phosphorylation in DRG neurons.  
A. Capsaicin-evoked TRPV1 activity was enhanced in primary DRG neurons 
cultured in 50mM glucose and this was prevented with VEGF-A165b co-
treatment (n=3 per treatment, 2 way ANOVA interaction F(28,90) = 1.081 (ns), 
treatment F(2,90)= 67.05, p<0.0001, time F(14, 90)= 3.842, p<0.0001, 
*p<0.05 vehicle cf. VEGF-A165b post hoc Tukey’s test). B. Total capsaicin-
evoked activity (AUC) was increased in high glucose conditions and reduced 
by VEGF-A165b (1 way ANOVA F(2,6)=9.424, p=0.014 *p<0.05 post hoc 
Sidak’s test). C. Representative Western blots for TRPV1 (96kD), pS800 
TRPV1 (95kD), and actin (42kD) in 50B11 DRG neurons treated for 24h in 
basal glucose (36mM + 30mM mannitol), high glucose (66mM) ± VEGF-A165b 
treatment (intervening lanes between markers and samples removed for 
clarity). D. Phosphorylated TRPV1 protein levels in 50B11 neurons increased 
in high glucose conditions compared to basal glucose conditions, and this was 
prevented with VEGF-A165b treatment (n=3 per treatment 1 way ANOVA 
F(2,6)=42.01 p<0.0003, *p<0.05, ***p<0.001 post hoc Sidak’s test). E. TRPV1 
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 protein levels in 50B11 neurons were slightly increased in high glucose + 
VEGF-A165b (one way ANOVA F(2,18)=3.637, p=0.047, n=9 in 36mM glucose 
& 66mM glucose + vehicle, n=3 for 66mM glucose + VEGF-A165b as shown, 
*p<0.05 post hoc Sidak’s test). Data shown are mean ± SEM, plus individual 
data points in B, D & E. (Please see methods text for different glucose 
concentrations in 50B11 and primary DRG neuronal cultures). 
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Figure 5. RAGE agonism and antagonism modulate capsaicin-evoked 
intracellular calcium changes in DRG neurons. A. FPSZM1 had no effect 
on capsaicin-evoked TRPV1 activity at any concentration in 10mM glucose 
conditions (n=4 per treatment). B. FPSZM1 significantly reduced the 
capsaicin-evoked TRPV1 activity in 50mM glucose conditions, in a 
concentration dependent manner (n=4 per treatment). C. The high glucose-
induced increase in TRPV1 activity was completely prevented when neurons 
were co-treated with 10nM FPSZM1 (n=4, 10mM glucose and 50mM glucose 
+ FPSZM1, n=5, 50mM glucose) (one way ANOVA F(2,10)=8.398, p=0.0072. 
*p<0.05, **p<0.01 post hoc Sidak’s test). D. HMGB1 increased the capsaicin-
evoked TRPV1 activity in a concentration-dependent manner (one way 
ANOVA F95,30) =2.688, p=0.04. *p<0.05 post-hoc Bonferroni tests c.f. 
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 control, n=6 per treatment). E. The HMGB1-mediated (10nM) increase in 
capsaicin-evoked TRPV1 activity was blocked by 10nM FPSZM1 (n=4 per 
treatment, one way ANOVA F(2,9)=42.63, p<0.0001). 
Data are mean ± SEM and individual data points as shown. *p<0.05. **p<0.01 
post-hoc Sidak’s tests. 
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Figure 6. HMGB1-mediated sensitization of capsaicin evoked TRPV1 
activity is PKC-dependent. A. BIM1 had no significant effect on capsaicin-
evoked calcium response alone, but significantly reduced HMGB1-evoked 
responses (one way ANOVA F=5.627, DF=3, p=0.0018. *p<0.05 c.f. 
HMGB1+BIM1 and control post hoc Bonferroni tests. Capsaicin + vehicle 
n=10, capsaicin + BIM1 n=19, capsaicin + HMGB1 + vehicle n=17, capsaicin 
+ HMGB1 + BIM1 n=20 as shown). B. VEGF-A165b significantly reduced 
HMGB1-mediated sensitization of capsaicin-evoked TRPV1 activity (one way 
ANOVA F(2,9)=14.2, p=0.0016. **p<0.01 post-hoc Sidak’s test). Data shown 
are mean ± SEM, n=4 per group. 
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Table 1. Antibody information 
 
Target Antibody type  Source and catalogue 
number 
Dilution Ref  
Primary antibodies – Western blotting 
TRPV1 Rabbit 
polyclonal 
 
Abcam (Ab10296) 1:500 (Hulse et al., 
2014) 
p800-
TRPV1 
Rabbit 
polyclonal  
Abnova (PAB8499) 1:250 (Mandadi et al., 
2006) 
HMGB1 Rabbit 
polyclonal 
Abcam (Ab18256) 1:1000 (Xiong et al., 
2016) 
Actin Goat 
polyclonal 
Santa Cruz  
(sc-1615) 
1:200 (Stanojlovic et 
al., 2016) 
Primary antibodies - immunofluorescence 
RAGE Rabbit 
polyclonal 
AbCam (Ab37647) 1:500 (Shirley et al., 
2014) 
NeuN Mouse 
monoclonal 
Millipore (MAB377) 1:200 (Krzisch et al., 
2015) 
Secondary antibodies – Western blotting 
Anti-
rabbit 
Donkey  Licor IRDye 680RD (926-
68071) 
1:1000 (Del Nagro et 
al., 2014) 
Anti-goat Donkey Licor IRDye 800CW 
(925-32214) 
1:1000 (Genead et al., 
2012) 
Secondary antibodies - immunofluorescence 
Anti-
rabbit 
Donkey Alexa Fluor 488-conjugated 
(AbCam Ab150073) 
1:500 (Zhang et al., 
2014) 
Anti-
mouse 
Chicken Alexa Fluor 555-conjugated 
(AbCam150114) 
1:500 (Na Pombejra et 
al., 2017) 
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Table S1. Representative data and effect sizes for outcome measures shown in the text. 
Effect sizes calculated using G*Power (Faul et al., 2007). 
Parameter 
Diabetic rat experiments 
Naïve/control 
Mean±SD (n) 
Diabetic 
Mean±SD(n) 
Diabetic+VEGF-A165b 
Mean±SD (n) 
Effect size (n) 
 (Cohen’s d) 
Figure 
Behaviour - thermal 12.9 ± 2.9 (11) 7.9 ± 1.2 (9) 11.7 ±2.1 (9) 1.05 (28) 1 
Behaviour – von Frey 13.4 ±7.2 (11) 4.5 ± 3.2 (9) 9.5 ± 4.3 (9) 0.74 (29) 1 
HMGB1 western blots 0.96±0.7 (5) 5.4 ± 3.6 (4) 3.7 ± 2.1 (4) 0.94 (13) 2B 
RAGE expression-% 62 ± 4.8 (4) 76 ± 4.1 (3) 76 ± 5.9 (3) 1.37 (11) 3B 
RAGE expression-intensity 17.8 ± 2.7 (4) 55.6 ± 9.7 (3) 35.2 ± 6.7 (3) 2.6 (11) 3C 
 
In vitro DRG/50B11 experiments 
Control 
Intervention 
(high glucose/ 
HMGB1) 
Intervention +  
VEGF-A165b/FPSZM1 
Effect size (n) Figure 
TRPV1 activity  
(DRG neurons) 
41.4 ± 7.3 (3) 78.3 ± 19.5 (3) 24.6 ± 17 (3) 1.32 (9) 5B 
TRPV1 
pTRPV1 (50B11 neurons) 
0.86 ± 0.09 (9) 
0.84 ± 0.14 (3) 
0.85 ± 0.07 (9) 
1.23 ±0.1 (3) 
1.002 ± 0.09 (3) 
0.38 ± 0.09 (3) 
0.56 (21) 
3.48 (9) 
5E 
5D 
TRPV1 activity (+HMGB1) 29 ± 9.6 (4) 121 ± 43 (4) 50 ± 5 (4) 3.93 (12) 8B 
TRPV1 activity  
(high glu ± FPSZM1) 
75.8 ± 25 (4) 189.9 ± 88 (5) 40.9 ± 9.3 (4) 2.42 (13) 6C 
TRPV1 activity  
(HMGB ± FPSZM1) 
29.1±4.8 (4) 90.4±4.1 (4) 22.8±7.7 (4) 2.65 (12) 7B 
Faul,	F.,	Erdfelder,	E.,	Lang,	A.	G.	and	Buchner,	A.	(2007).	G*Power	3:	a	flexible	statistical	power	analysis	program	for	the	
social,	behavioral,	and	biomedical	sciences.	Behav	Res	Methods	39,	175-91.	
J. Cell Sci. 131: doi:10.1242/jcs.215939: Supplementary information
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Figure S1 
The antibody used for RAGE immunofluorescent staining of DRG neurons in Figure 2 was verified for specificity in immortalised rat DRG 
50B11 neurons. This confirmed that the antibody detected a single band of size ~45kD. B= basal glucose (36mM), H = high glucose (66mM) 
B BH H
75
50
37
75
50
37
RAGE 
ACTIN 
J. Cell Sci. 131: doi:10.1242/jcs.215939: Supplementary information
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